NASDAQ:VRCA - Verrica Pharmaceuticals Stock Price, News & Analysis

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.28) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.30) by $0.02. View Verrica Pharmaceuticals' Earnings History.

Verrica Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Verrica Pharmaceuticals.

1 Wall Street analysts have issued twelve-month price objectives for Verrica Pharmaceuticals' shares. Their forecasts range from $23.00 to $23.00. On average, they expect Verrica Pharmaceuticals' share price to reach $23.00 in the next year. This suggests a possible upside of 155.3% from the stock's current price. View Analyst Price Targets for Verrica Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verrica Pharmaceuticals.

Media stories about VRCA stock have trended negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Verrica Pharmaceuticals earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Verrica Pharmaceuticals.

Verrica Pharmaceuticals saw a drop in short interest in July. As of July 15th, there was short interest totalling 606,200 shares, a drop of 16.3% from the June 15th total of 724,400 shares. Based on an average daily trading volume, of 50,300 shares, the short-interest ratio is currently 12.1 days. Currently, 5.0% of the company's stock are short sold. View Verrica Pharmaceuticals' Current Options Chain.

Some companies that are related to Verrica Pharmaceuticals include Principia Biopharma (PRNB), Emisphere Technologies (EMIS), Axsome Therapeutics (AXSM), Spectrum Pharmaceuticals (SPPI), ANI Pharmaceuticals (ANIP), ZIOPHARM Oncology (ZIOP), OrganiGram (OGI), Eagle Pharmaceuticals (EGRX), Alder Biopharmaceuticals (ALDR), Cytokinetics (CYTK), Vanda Pharmaceuticals (VNDA), Kura Oncology (KURA), Arvinas (ARVN), CannTrust (CNTTF) and Retrophin (RTRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include Johnson & Johnson (JNJ), Thermo Fisher Scientific (TMO), Amgen (AMGN), Home Depot (HD), Honeywell International (HON), Raytheon (RTN), Verizon Communications (VZ), Cisco Systems (CSCO), CSX (CSX) and Texas Instruments (TXN).

(VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.

Verrica Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.46%), Kornitzer Capital Management Inc. KS (1.88%), Vanguard Group Inc. (1.78%), Point72 Asset Management L.P. (0.55%), Asymmetry Capital Management L.P. (0.52%) and Northern Trust Corp (0.43%). Company insiders that own Verrica Pharmaceuticals stock include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Matt Davidson, Paul B Manning, Sean Stalfort and Ted White. View Institutional Ownership Trends for Verrica Pharmaceuticals.

VRCA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P.. View Insider Buying and Selling for Verrica Pharmaceuticals.

VRCA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Asymmetry Capital Management L.P., Kornitzer Capital Management Inc. KS, Vanguard Group Inc., Wells Fargo & Company MN, Bank of America Corp DE, Bank of New York Mellon Corp and Northern Trust Corp. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Paul B Manning, Sean Stalfort and Ted White. View Insider Buying and Selling for Verrica Pharmaceuticals.

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of VRCA stock can currently be purchased for approximately $9.01.

Verrica Pharmaceuticals has a market capitalization of $231.92 million. The company earns $-20,650,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Verrica Pharmaceuticals employs 16 workers across the globe.View Additional Information About Verrica Pharmaceuticals.

The official website for Verrica Pharmaceuticals is http://www.verrica.com/.

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]